<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608682</url>
  </required_header>
  <id_info>
    <org_study_id>WJP20201030</org_study_id>
    <nct_id>NCT04608682</nct_id>
  </id_info>
  <brief_title>Effect of Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Monitoring</brief_title>
  <official_title>Effect of Intraoperative Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial motor evoked potential (TcMEP) monitoring is conventionally performed during&#xD;
      surgery without or with minimal neuromuscular blockade (NMB) because of its potential&#xD;
      interference with signal interpretation.The feasibility of TcMEP interpretation was assessed&#xD;
      during partial NMB in adult neurosurgical patients. However, partial NMB may interfere record&#xD;
      of TcMEP monitoring. Sugammadex is the first highly selective antagonist that can reverse&#xD;
      NMB. This study aims to evaluate the success rate of intraoperative muscle relax reversal by&#xD;
      sugammadex on intraoperative TceMEP monitoring.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate of TceMEPs monitoring</measure>
    <time_frame>5 minutes after dura opening</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Sugammadex</condition>
  <condition>Motor Evoked Potentials</condition>
  <arm_group>
    <arm_group_label>Sugammadex group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>The muscle relaxant infusion will be discontinued and 2 mg/kg of sugammadex will be infused, TceMEPs monitoring will be performed 5 minutes later.</description>
    <arm_group_label>Sugammadex group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range from 18 to 65 years old&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status I to II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI â‰¥35 kg/m-2&#xD;
&#xD;
          -  History of epilepsy or use of antiepileptic drugs&#xD;
&#xD;
          -  Personal history or family history of malignant hyperthermia&#xD;
&#xD;
          -  Allergies to sugammadex; NMBs or other medication(s) used during general anesthesia&#xD;
&#xD;
          -  Hemoglobin &lt;110 g/L&#xD;
&#xD;
          -  TceMEP stimulation or recorded site infection&#xD;
&#xD;
          -  Preoperative neurological dysfunction in both upper extremities&#xD;
&#xD;
          -  Cardiac pacemaker&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruquan Han, Dr.</last_name>
    <phone>+8610 59976660</phone>
    <email>ruquan.han@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <phone>8610-59976660</phone>
      <email>ruquan.han@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3 months after the study is finished</ipd_time_frame>
    <ipd_access_criteria>principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

